Medrio to Announce Accelerated Global Expansion on the Heels of Successful 2017

SAN FRANCISCO, CA-February 14, 2018-Medrio, Inc. a leading healthcare technology company providing eClinical solutions for clinical trials, announced today the company’s international and domestic channel expansion, which includes EMEA and APAC. On the heels of an exceptional year, Medrio is solidifying the company’s leadership position across pharmaceutical, medical devices, diagnostics and animal health sponsors and CROs.

2017 was a big year for Medrio, as the company closed a $30 million equity investment from Questa Capital Management, a venture capital firm focused on investing in growth-stage healthcare companies. The investment marked the company’s first infusion of institutional capital in its twelve-year history. 

“With new and complicated data privacy regulations being issued across the globe, the data stemming from international clinical trials needs to be streamlined in a way that meets all the guidelines necessary to take a new product or device to market,” said Mike Novotny, Founder and Chief Executive Officer of Medrio. “As Medrio continues to grow, increasing our international presence is essential to meeting our goals of adding speed, consistency and security to the data aggregation and analysis process.”

To meet increasing demand, including from enterprise-level organizations, both domestically and internationally, the company is opening offices in Charlotte, North Carolina; Heidelberg, Germany; and Tokyo, Japan, and is adding strategic business development headcount, including but not limited to:

●      Rob Akers, Vice President of Business Development

●      Lewis Baird, Senior Director, Business Development

●      Shinya Yamamoto, Managing Director, Asia Pacific

These representatives will help take Medrio’s existing international momentum to the next level. This momentum has, in recent months, yielded new partnerships in up-and-coming clinical research destinations such as APAC. Linear Clinical Research, a research company based in Perth, Australia, last year implemented Medrio as their first departure from paper-based data capture. “Our EDC and eSource implementation has created interest within the CRO and sponsor communities,” says Simone Knab, Digital Strategy Lead at Linear Clinical Research. “They understand we’re trying to gain efficiencies, create seamless data flow, and demonstrate to the industry how we can get data results quicker so we can get them to the FDA quicker and drugs can reach the market quicker.”

As Medrio leverages the expanded sales team to capitalize on increased demand in the US and overseas, the company will continue to invest in expansion of its best-in-class eClinical tools. With Medrio’s EDC, eSource, and ePRO products, sponsors and CROs have the fastest, most flexible, and easy-to-use eClinical tools on the market. 

About Medrio Inc.
Medrio Inc. is a leading healthcare technology company that provides eClinical solutions
including electronic data capture (EDC) and eSource for clinical trials. The company’s software platform and mobile suite of products deliver simple, fast, and affordable tools for study sponsors and contract research organizations (CROs) to collect clinical trial data. Medrio has extensive experience in all study phases with its software leading the way in early-phase trials. The company serves over 500 customers globally. For more information, please visit www.medrio.com.

Media Contact:

Danielle Ostrovsky

Hi-Touch PR

Ostrovsky@hi-touchpr.com

410-302-9459